Relay Therapeutics (RLAY) closed at $18.09 on November 13, 2026, up 0.1% from the previous close, on volume of 1,403,975 shares (30-day average 2,528,496).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 23, 2026 | Put with Delta Hedge | 19-Mar-27 20 P +23,000 Stock | 500 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
Globe Newswire (Wed, 4-Nov 4:05 PM ET)
Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November
Globe Newswire (Mon, 2-Nov 4:05 PM ET)
Globe Newswire (Wed, 28-Oct 4:12 PM ET)
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
Globe Newswire (Tue, 1-Sep 4:46 PM ET)
Relay Therapeutics’ $275 Million Offering: What the Major Capital Raise Signals for RLAY
Market Chameleon (Thu, 21-May 6:32 AM ET)
Relay Therapeutics' Zovegalisib Shows 60% Early Response Rate in Rare Vascular Anomaly Trial
Market Chameleon (Tue, 19-May 6:11 AM ET)
Market Chameleon (Mon, 16-Mar 3:53 AM ET)
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Relay Therapeutics trades on the NASDAQ stock market under the symbol RLAY.
As of November 13, 2026, RLAY stock price climbed to $18.09 with 1,403,975 million shares trading.
RLAY has a beta of 1.61, meaning it tends to be more sensitive to market movements. RLAY has a correlation of 0.11 to the broad based SPY ETF.
RLAY has a market cap of $3.96 billion. This is considered a Mid Cap stock.
Last quarter Relay Therapeutics reported $0 in Revenue and -$.37 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.03.
In the last 3 years, RLAY traded as high as $21.27 and as low as $1.78.
The top ETF exchange traded funds that RLAY belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
RLAY has outperformed the market in the last year with a return of +180.5%, while the SPY ETF gained +13.4%. However, in the most recent history, RLAY shares have underperformed the stock market with its stock returning -9.2% in the last 3 month period and -1.4% for the last 2 week period, while SPY has returned -2.8% and -0.2%, respectively.
RLAY support price is $17.19 and resistance is $18.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RLAY shares will trade within this expected range on the day.